You don’t need to find a vein to take your dose of HEMLIBRA.
— Maria, mom of 13-year-old with hemophilia A without factor VIII inhibitors, Texas
HEMLIBRA Clinical Education Managers (CEMs) have years of nursing/clinical experience.
Use this handy discussion guide to get the most out of your conversation.
The term “half-life” in medicine means how long it takes for half the amount of a drug to leave the body. A longer half-life means the medicine stays in your body longer.
The half-life of HEMLIBRA is 646 hours, or about 4 weeks.
The half-life of factor VIII treatment can be up to 22 hours.
Lower levels of HEMLIBRA in blood were predicted in children less than 6 months old.
— Guy Young, MD, Keck School of Medicine of the University of Southern California
*For all 3 dosing groups, the levels of HEMLIBRA were within the therapeutic range. A therapeutic range is the range of drug levels that may be expected to achieve a therapeutic treatment effect.
For the first 4 weeks of treatment, you’ll use HEMLIBRA once a week. This will build up the levels of HEMLIBRA in your blood. After that, your doctor will help you choose a dosing schedule that’s right for you.
For more information on your HEMLIBRA dosing schedules, click here.
— Gabe, 36-year-old man with hemophilia A without factor VIII inhibitors, Texas
Gabe takes HEMLIBRA every 2 weeks, after having completed the 4 once weekly loading doses.
Please see HEMLIBRA Instructions for Use for full dosing and administration information.
Individual results may vary. Not all patients in the clinical trials had zero bleeds. See results for clinical trial patients with or without factor VIII inhibitors here.
The HEMLIBRA community members shown have been compensated for their participation.
When starting HEMLIBRA, a “loading dose” is taken once weekly for 4 weeks. After that, HEMLIBRA offers 3 regular dosing options: once weekly, once every 2 weeks, or once every 4 weeks. Talk to a doctor about dosing.
Link to Healthcare Professionals Site
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
Link to Third-Party Site
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.